Answers are grounded in this paper and cite their sources.
A "second generation" γ-secretase, Begacestat (GSI-953), which is more selective against Notch-signaling, has shown promise in recent Phase I clinical trials. Begacestat, a novel, 2,5-disubsitituted thiophene sulfonamide from Wyeth (now Pfizer) is under evaluation for the treatment of Alzheimer's disease.
No takes yet. Share an insight, caveat, or question.
Corey R. Hopkins (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: